热门出版物
h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2017-2021 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏
出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏
标题/作者引用次数年份
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1Hyperprogressive Disease with Anti-PD-1/PD-L1 Therapy
S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ...
Clinical Cancer Research 23 (8), 1920-1928
9242017
Allele-specific HLA loss and immune escape in lung cancer evolution
N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ...
CLINICAL CANCER RESEARCH 24 (17)
7172018
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth RateGenomics of Immunotherapy-Associated Hyperprogressors
S Kato, A Goodman, V Walavalkar, DA Barkauskas, A Sharabi, ...
Clinical Cancer Research 23 (15), 4242-4250
6682017
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 InhibitionMultiplex Genome Editing to Generate Universal CAR T Cells
J Ren, X Liu, C Fang, S Jiang, CH June, Y Zhao
Clinical Cancer Research 23 (9), 2255-2266
6392017
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionPARPi Upregulates PD-L1 Expression
S Jiao, W Xia, H Yamaguchi, Y Wei, MK Chen, JM Hsu, JL Hsu, WH Yu, ...
Clinical Cancer Research 23 (14), 3711-3720
5482017
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
ZY Dong, WZ Zhong, XC Zhang, J Su, Z Xie, SY Liu, HY Tu, HJ Chen, ...
Clinical Cancer Research 23 (12), 3012-3024
5452017
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsFDA Approval Summary: Pembrolizumab for MSI-H Solid Tumors
L Marcus, SJ Lemery, P Keegan, R Pazdur
Clinical Cancer Research 25 (13), 3753-3758
5412019
Deep Learning–Based Multi-Omics Integration Robustly Predicts Survival in Liver CancerUsing Deep Learning to Predict Liver Cancer Prognosis
K Chaudhary, OB Poirion, L Lu, LX Garmire
Clinical Cancer Research 24 (6), 1248-1259
5082018
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast CancerPhase II Study of Abemaciclib in HR+/HER2− MBC
MN Dickler, SM Tolaney, HS Rugo, J Cortés, V Diéras, D Patt, H Wildiers, ...
Clinical Cancer Research 23 (17), 5218-5224
4532017
Oxidative Phosphorylation as an Emerging Target in Cancer Therapy
TM Ashton, WG McKenna, LA Kunz-Schughart, GS Higgins
Clinical Cancer Research 24 (11), 2482-2490
4402018
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
JH Yearley, C Gibson, N Yu, C Moon, E Murphy, J Juco, J Lunceford, ...
Clinical Cancer Research 23 (12), 3158-3167
3762017
Breast Cancer Immunotherapy: Facts and HopesBreast Cancer Immunotherapy
LA Emens
Clinical Cancer Research 24 (3), 511-520
3762018
Circular RNA ciRS-7—A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal CancerciRS-7 in Colorectal Cancer
W Weng, Q Wei, S Toden, K Yoshida, T Nagasaka, T Fujiwara, S Cai, ...
Clinical Cancer Research 23 (14), 3918-3928
3562017
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine TumorsEfficacy, Survival, and Toxicity after 177Lu-DOTATATE
T Brabander, WA van der Zwan, JJM Teunissen, BLR Kam, RA Feelders, ...
Clinical Cancer Research 23 (16), 4617-4624
3512017
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer PatientsPD-L1+ Exosomes in Plasma of HNC Patients
MN Theodoraki, SS Yerneni, TK Hoffmann, WE Gooding, TL Whiteside
Clinical Cancer Research 24 (4), 896-905
3512018
Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal CarcinomaPretreatment Radiomics for Nasopharyngeal Carcinoma
B Zhang, J Tian, D Dong, D Gu, Y Dong, L Zhang, Z Lian, J Liu, X Luo, ...
Clinical Cancer Research 23 (15), 4259-4269
3492017
Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation SequencingExosomal miRNA as Early Diagnostic Biomarkers for NSCLC
X Jin, Y Chen, H Chen, S Fei, D Chen, X Cai, L Liu, B Lin, H Su, L Zhao, ...
Clinical Cancer Research 23 (17), 5311-5319
3442017
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
CP Kratz, MI Achatz, L Brugières, T Frebourg, JE Garber, MLC Greer, ...
Clinical Cancer Research 23 (11), e38-e45
3372017
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine GliomasAnti-PD-1, Anti-TIM-3, and Radiation in Glioma Model
JE Kim, MA Patel, A Mangraviti, ES Kim, D Theodros, E Velarde, A Liu, ...
Clinical Cancer Research 23 (1), 124-136
3312017
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human CancersWNT/β-catenin–Associated Immune Exclusion across Cancers
JJ Luke, R Bao, RF Sweis, S Spranger, TF Gajewski
Clinical Cancer Research 25 (10), 3074-3083
3242019
1 - 20
计算机程序会自动估算并确定日期和引用次数。